Specialist in Operative Urology, surgeon, clinical researcher, and expert in urinary biomarkers, precision medicine, and regenerative medicine in urology.
Alain Mottaz, MD, has built a career at the intersection of clinical practice, academic research, medical innovation, and collaboration with the healthcare industry.
Trained in Lausanne, he specialised in urology at Inselspital Bern before completing a fellowship in urologic oncology at Baylor College of Medicine in Houston, Texas. He has also held clinical and academic positions at the University of Bern.
His work spans urologic oncology surgery, functional urology, urinary reconstruction, urinary biomarkers, precision medicine, and regenerative medicine in urology.
Alain Mottaz, MD, is also Chief Medical Officer and board member at Holisan, and Chief Medical Officer at the Centre Lémanique d’Urologie in Lausanne. He was previously co-founder of Gene Predictis SA, a pioneering company in predictive diagnostics and pharmacogenetics.
A consistent theme throughout Dr Mottaz’s career has been his ability to bridge scientific evidence and clinical practice. This expertise is particularly relevant in the field of biotherapies, where patient expectations must be considered alongside a thorough evaluation of indications, limitations and the available evidence.
Holisan’s approach is built on the same principle: providing a comprehensive urological evaluation, clearly explaining the available options, recommending treatment only when appropriate, and ensuring structured, documented follow-up.
